Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BlackRock Health Sciences Trust II (BMEZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: BMEZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 19.47% | Avg. Invested days 75 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.46B USD | Price to earnings Ratio 68.67 | 1Y Target Price - |
Price to earnings Ratio 68.67 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 12.58 - 16.75 | Updated Date 06/29/2025 |
52 Weeks Range 12.58 - 16.75 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 14.07% | Basic EPS (TTM) 0.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 68.67 | Forward PE - | Enterprise Value - | Price to Sales(TTM) 59.22 |
Enterprise Value - | Price to Sales(TTM) 59.22 | ||
Enterprise Value to Revenue 53.02 | Enterprise Value to EBITDA - | Shares Outstanding 101255000 | Shares Floating - |
Shares Outstanding 101255000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions 35.87 |
Upturn AI SWOT
BlackRock Health Sciences Trust II
Company Overview
History and Background
BlackRock Health Sciences Trust II (BKN) is a closed-end fund managed by BlackRock Advisors, LLC. It focuses on investing in a diversified portfolio of equity securities of companies engaged in the health sciences sector. The trust aims to provide income and capital appreciation by investing in companies involved in pharmaceuticals, biotechnology, medical devices, healthcare services, and other related industries. Information on its specific founding year and significant early milestones is not readily available as it operates as a diversified investment trust under the BlackRock umbrella. Its evolution is tied to BlackRock's broader strategy in offering specialized sector-focused investment vehicles.
Core Business Areas
- Pharmaceuticals: Investments in companies that develop, manufacture, and market prescription drugs and over-the-counter medications.
- Biotechnology: Investments in companies focused on genetic engineering, diagnostic tools, and therapeutic treatments derived from biological processes.
- Medical Devices and Equipment: Investments in companies that produce medical instruments, diagnostic equipment, and supplies used in healthcare settings.
- Healthcare Services and Facilities: Investments in entities that provide healthcare delivery, such as hospitals, clinics, managed care organizations, and related support services.
- Life Sciences Tools and Services: Investments in companies that provide essential tools, software, and services for research and development in the life sciences.
Leadership and Structure
BlackRock Health Sciences Trust II is managed by a team of portfolio managers at BlackRock, a global investment management corporation. The specific leadership team for this trust includes individuals responsible for research, portfolio construction, and risk management within the health sciences sector. As a closed-end fund, its structure involves a fixed number of shares that trade on an exchange, influenced by market supply and demand, and managed with a long-term investment objective.
Top Products and Market Share
Key Offerings
- Product Name 1: Diversified Health Sciences Equity Portfolio. This is the primary offering, consisting of a basket of publicly traded equity securities in the health sciences industry. Market share data for a specific trust's portfolio is not applicable in the traditional sense. Competitors would be other health sciences focused ETFs and mutual funds, as well as actively managed health sciences strategies from other asset managers.
Market Dynamics
Industry Overview
The health sciences industry is characterized by rapid innovation, significant research and development expenditure, stringent regulatory environments, and an aging global population that drives demand for healthcare services and products. Key trends include advancements in genomics, personalized medicine, digital health, and the growing importance of emerging markets. The industry is also subject to policy changes, patent expirations, and competitive pressures.
Positioning
BlackRock Health Sciences Trust II is positioned as an actively managed investment vehicle offering diversified exposure to the health sciences sector. Its competitive advantage lies in BlackRock's extensive research capabilities, global reach, and expertise in various investment strategies. It aims to outperform broad market indices by identifying promising companies within the dynamic health sciences landscape.
Total Addressable Market (TAM)
The total addressable market for the health sciences sector is exceptionally large and continues to grow. While a precise dollar figure for the TAM is difficult to pinpoint due to its broad scope, the global healthcare market alone is projected to be trillions of dollars annually. BlackRock Health Sciences Trust II, by investing in a diversified portfolio of equities within this sector, aims to capture a portion of the growth and value creation within this vast market. Its positioning is as a specialist fund seeking alpha within this specific industry.
Upturn SWOT Analysis
Strengths
- Access to BlackRock's extensive research capabilities and global network.
- Diversified exposure to a broad range of health sciences sub-sectors.
- Active management approach seeking to identify undervalued or high-growth potential companies.
- Potential for income generation through dividends and capital appreciation.
Weaknesses
- Closed-end fund structure can lead to trading at a premium or discount to Net Asset Value (NAV).
- Performance is dependent on the ability of portfolio managers to select winning stocks in a highly competitive sector.
- Management fees can impact overall returns.
- Sector-specific risks can lead to volatility if the health sciences industry faces headwinds.
Opportunities
- Continued innovation and technological advancements in biotechnology and pharmaceuticals.
- Increasing global demand for healthcare services driven by aging populations and rising incomes.
- Potential for consolidation and M&A activity within the health sciences sector.
- Emerging markets growth in healthcare spending.
- Development of new treatments for unmet medical needs.
Threats
- Regulatory changes and government policy shifts impacting drug pricing and healthcare access.
- Patent expirations leading to generic competition.
- Intense competition and high R&D failure rates.
- Economic downturns affecting healthcare spending.
- Geopolitical risks impacting global supply chains and market access.
Competitors and Market Share
Key Competitors
- Fidelity Select Pharmaceuticals Portfolio (FPHGP)
- Vanguard Health Care Fund (VGHCX)
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
Competitive Landscape
BlackRock Health Sciences Trust II competes in a landscape with numerous actively managed funds, ETFs, and individual stock options for investors seeking exposure to the health sciences sector. Its advantages lie in BlackRock's brand recognition and analytical resources. However, it faces stiff competition from both other actively managed funds and passively managed ETFs which often have lower expense ratios. The key differentiator is the active management's ability to generate alpha.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for BlackRock Health Sciences Trust II is reflected in the performance of its NAV per share and market price over time. This is heavily influenced by the performance of the health sciences sector and the effectiveness of the portfolio management.
Future Projections: Future projections are dependent on analyst expectations for the health sciences sector and BlackRock's investment strategy. These projections are not typically provided at the fund level but are inferred from sector-wide growth forecasts and the fund's investment mandate.
Recent Initiatives: Recent initiatives would likely involve portfolio adjustments, rebalancing based on market outlook, and potentially changes to distribution policies. Specific new initiatives are announced by BlackRock as needed to adapt to market conditions or regulatory changes.
Summary
BlackRock Health Sciences Trust II is a specialized investment trust focused on the dynamic health sciences sector. Its strength lies in BlackRock's extensive research and diversified portfolio approach. However, it faces challenges common to closed-end funds, including potential discounts to NAV and management fees. The sector's inherent volatility and regulatory risks are key factors for investors to consider. Continued innovation in health sciences presents significant opportunities, but careful navigation of the competitive and regulatory landscape is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BlackRock Investor Relations
- Financial news and data providers (e.g., Bloomberg, Refinitiv)
- Industry analysis reports
Disclaimers:
This JSON output is generated based on publicly available information and general industry knowledge. It is not intended as investment advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share data for individual investment trusts is often not precisely quantifiable in the same way as for operating companies; the provided figures are illustrative of competitive positioning.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BlackRock Health Sciences Trust II
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-01-29 | CEO - | ||
Sector Financial Services | Industry Asset Management | Full time employees - | Website |
Full time employees - | Website | ||
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.